Filing scope and business context
Registrant: I-Mab (Nasdaq: IMAB), a Cayman Islands holding company operating primarily through subsidiaries in China and the United States. The supplied metadata names Novabridge Biosciences, but the filing itself is I-Mab’s Form 20-F. This is an annual report for the fiscal year ended December 31, 2021—not a quarterly report. Filed April 29, 2022; financial statements are prepared under U.S. GAAP and reported in RMB, with U.S. dollar translations provided.
I-Mab is a clinical-stage biopharmaceutical company focused on biologics, especially immuno-oncology and immuno-inflammatory diseases. It had no approved products and no revenue from commercial product sales in 2021.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | RMB 88.0 million (US$13.8 million) | RMB 1,542.7 million |
| Operating income (loss) | RMB (2,071.3) million | RMB 155.6 million |
| Net income (loss) | RMB (2,331.5) million (US$365.9 million) | RMB 470.9 million |
| Research and development expense | RMB 1,213.0 million | RMB 984.7 million |
| Administrative expense | RMB 899.9 million | RMB 402.4 million |
| Net cash from (used in) operating activities | RMB (973.1) million | RMB 433.6 million |
| Net cash from (used in) investing activities | RMB (727.2) million | RMB (201.9) million |
| Net cash from financing activities | RMB 593.9 million | RMB 3,440.5 million |
2021 revenue comprised RMB 40.1 million of licensing and collaboration revenue and RMB 47.9 million from supplying investigational products; cost of revenue was RMB 46.4 million. The resulting gross profit was RMB 41.6 million, though this margin is not necessarily indicative of future product economics given the revenue mix and absence of commercial product sales.
At year-end, cash and cash equivalents were RMB 3.524 billion and short-term investments were RMB 753.2 million, or RMB 4.277 billion combined. Current assets were RMB 4.782 billion; current liabilities were RMB 624.0 million. Total liabilities were RMB 1.042 billion, including lease liabilities, contract liabilities and a put-right liability. The balance sheet does not present a separate material interest-bearing debt balance; interest expense was zero in 2021. Operating lease commitments were RMB 122.6 million and capital commitments RMB 24.4 million.
Material changes versus 2020
- Revenue fell to RMB 88.0 million from RMB 1.543 billion, primarily because 2020 included substantial revenue recognized under the AbbVie collaboration. 2021 licensing and collaboration revenue was RMB 40.1 million; investigational-product supply to AbbVie contributed RMB 47.9 million.
- The company swung from 2020 net income of RMB 470.9 million to a 2021 net loss of RMB 2.332 billion. 2020 results included a RMB 407.6 million gain on deconsolidating I-Mab Hangzhou; this gain did not recur.
- R&D expense rose 23.2% to RMB 1.213 billion, mainly as CRO services and in-licensed fees increased. Administrative expense rose to RMB 899.9 million, driven in part by higher share-based compensation, Tracon-related legal costs and an accrued termination fee.
- Operating cash flow changed from a positive RMB 433.6 million to an outflow of RMB 973.1 million. Cash and cash equivalents declined from RMB 4.759 billion to RMB 3.524 billion, while short-term investments rose from RMB 31.5 million to RMB 753.2 million.
- Share-based compensation expense was RMB 621.9 million in 2021, compared with RMB 526.2 million in 2020. Equity-method losses, primarily related to I-Mab Hangzhou, increased to RMB 367.9 million from RMB 108.6 million.
Outlook, management commentary, risks and unusual items
- Funding outlook: The selected financial data says cash, cash equivalents and short-term investments of RMB 4.3 billion were expected to support key business for at least three years, based on management’s estimate and anticipated milestone receipts. Elsewhere, the liquidity discussion says current cash and cash equivalents are expected to cover anticipated needs for at least 12 months. These are different measures and statements; the filing does not reconcile the differing time horizons. Management expects continued losses and higher spending as development and commercialization preparations advance.
- Pipeline and targets: Management described 20 clinical and preclinical assets, including ten clinical-stage assets and seven in Phase 2 or Phase 3. It targeted three NDA submissions and/or product launches in China between 2023 and 2025, including felzartamab, eftansomatropin alfa and potentially lemzoparlimab. These are forward-looking targets, not assured outcomes. Felzartamab’s 2021 year-end filing discussion anticipated an NDA submission in 2022; eftansomatropin alfa’s Phase 3 enrollment was expected to complete in Q2 2022, with an NDA targeted for 2023 or 2024.
- Collaboration economics: The 2020 AbbVie agreement provides potential future development, regulatory and sales milestones, but receipt and timing are contingent. The 2021 Jumpcan agreement for eftansomatropin alfa provides an upfront RMB 224 million and up to RMB 1.792 billion in milestone payments, plus a 50/50 profit-sharing arrangement in mainland China. The upfront payment was recorded as a contract liability, not 2021 revenue.
- Tracon dispute: I-Mab accrued a US$9 million (RMB 57.4 million) termination fee related to the TJD5 agreement and recorded it in administrative expense. Related disputes under the TJD5 and bispecific-antibody agreements were in binding arbitration; the company said the outcome was uncertain and anticipated a decision in late 2022. The filing reported no recorded liability for any additional potential loss.
- China and listing risks: The company cautioned about evolving PRC oversight, potential offshore-offering filing or approval requirements, restrictions on transferring cash from China, and the PCAOB’s inability at that time to inspect its China-based auditor. It expected to be identified under the HFCAA and discussed potential U.S. trading prohibition and delisting if inspection restrictions persisted. It said it was considering a PCAOB-inspectable U.S.-based auditor for a later annual report; regulatory outcomes remained uncertain.
- Clinical and operating risks: All product candidates remained investigational; clinical failure, safety issues, regulatory delay, competition, manufacturing execution, third-party dependence, intellectual-property disputes and reimbursement or pricing restrictions could impair development or commercialization. COVID-19 and related restrictions could disrupt trials, staffing and partners, although management said impacts on 2021 operations had not been material.
- Other notable items: The Hangzhou biologics facility was under construction, with staged capacity and operating dates presented as targets. I-Mab reported no dividends paid and no current plan to pay cash dividends in the foreseeable future. Its auditor issued unqualified opinions on the financial statements and internal control over financial reporting, and management reported controls effective at December 31, 2021.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the filing is I-Mab’s FY2021 Form 20-F, despite the supplied Novabridge Biosciences metadata and “2021 Q4” label.
- Reconcile management’s stated cash runway of at least three years with the liquidity section’s at-least-12-month estimate, including assumptions about spending and milestone receipts.
- Track cash burn, short-term investment liquidity and restrictions on moving PRC subsidiary funds offshore; distinguish cash and cash equivalents from the broader cash-plus-investments figure.
- Verify the timing and regulatory status of the targeted NDA filings and launches, particularly felzartamab, eftansomatropin alfa and lemzoparlimab; do not treat management targets as guidance guarantees.
- Monitor the Tracon arbitration and any resulting payments, licensing consequences or development restrictions.
- Monitor PCAOB inspection, HFCAA, CSRC filing and other PRC regulatory developments that could affect Nasdaq trading, capital raising or cross-border operations.
- Assess dilution from share-based compensation and outstanding awards, and confirm which collaboration milestones and royalties are contingent rather than received or recognized revenue.